GLP-1 Collective

Policy Tracker · Patient Lens · July 10, 2026

Six more patients take their Ozempic complaints to court

The lawsuits pile up faster than any single verdict, and each new filing adds pressure on what drugmakers must disclose about cost and effects.

6 developments affecting GLP-1 access were tracked on Thursday, July 9, 2026, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Patient sues Novo Nordisk over GLP-1 pricing and marketing](/lawsuits/cl-73602720)**.

**[Patient sues Novo Nordisk over Ozempic pricing and marketing](/lawsuits/cl-73601374)**.

**[Barfield Souther sues Eli Lilly over GLP-1 conduct](/lawsuits/cl-73599907)**.

**[Novo Nordisk sued over GLP-1 marketing and pricing claims](/lawsuits/cl-73599441)**.

**[Scanlon sues Eli Lilly over GLP-1 pricing and marketing](/lawsuits/cl-73603791)**.

**[Patient sues Novo Nordisk over GLP-1 drug practices](/lawsuits/cl-73603226)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.